Status:
COMPLETED
Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Rheumatoid Arthritis
Eligibility:
MALE
50+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.
Eligibility Criteria
Inclusion
- Body Mass index (BMI) 18-30 kg/m2, inclusive.
- Clinically normal findings in physical examination, ECG, vital signs, clinical chemistry, haematology \& urinalysis, as judged by the investigator
Exclusion
- Healthy volunteers who have been exposed to radiation levels above background (eg through X-ray examination) of \>5 mSv in the last year, \>10 mSv over the last 5 years or a cumulative total of \>1 mSv per year of life
- Clinically significant illness within the 2 weeks prior to dosing, as judged by the investigator
- Use of prescribed medication (including St. John's Wort) during the 3 weeks prior to dosing or use of over the counter drugs (including herbals, vitamins and minerals) during 1 week prior to dosing (other than occasional paracetamol use)
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00711074
Start Date
June 1 2008
End Date
July 1 2008
Last Update
April 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Macclesfield, Cheshire, United Kingdom